Do Traders Think Cara Therapeutics Inc (CARA) Can Turn Around Tuesday?

Tuesday, November 30, 2021 10:09 AM | InvestorsObserver Analysts

Mentioned in this article

Cara Therapeutics Inc (CARA) stock has fallen 2.86% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Cara Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CARA!
See Full CARA Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CARA Stock Today?

Cara Therapeutics Inc (CARA) stock is up 5.25% while the S&P 500 is lower by -0.5% as of 10:09 AM on Tuesday, Nov 30. CARA is higher by $0.63 from the previous closing price of $12.58 on volume of 98,847 shares. Over the past year the S&P 500 has gained 27.90% while CARA is lower by -9.75%. CARA earned $0.44 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 30.12.

More About Cara Therapeutics Inc

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. Click Here to get the full Stock Report for Cara Therapeutics Inc stock.

Share this article:

Related Articles